Cargando…

Post hoc analysis of reactogenicity trends between dose 1 and dose 2 of the adjuvanted recombinant zoster vaccine in two parallel randomized trials

In two large clinical trials (ZOE-50 [NCT01165177] and ZOE-70 [NCT01165229]), two doses of the adjuvanted recombinant zoster vaccine (RZV) demonstrated >90% efficacy against herpes zoster in adults ≥50 years of age. Solicited adverse events (AEs) were collected for 7 days post-each dose in a stud...

Descripción completa

Detalles Bibliográficos
Autores principales:	Colindres, Romulo, Wascotte, Valentine, Brecx, Alain, Clarke, Christopher, Hervé, Caroline, Kim, Joon Hyung, Levin, Myron J., Oostvogels, Lidia, Zahaf, Toufik, Schuind, Anne, Cunningham, Anthony L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2020
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7733973/ https://www.ncbi.nlm.nih.gov/pubmed/32347767 http://dx.doi.org/10.1080/21645515.2020.1741312

Ejemplares similares

2780. Reactogenicity Profile of Adjuvanted Recombinant Zoster Vaccine after Dose 2 According to the Intensity of the Same Event Experienced after Dose 1
por: Colindres, Romulo, et al.
Publicado: (2019)

2779. Efficacy of the Adjuvanted Recombinant Zoster Vaccine According to Sex, Geographic Region, and Geographic Ancestry/Ethnicity: A Post-hoc Analysis
por: Willer, David O, et al.
Publicado: (2019)

Association Between Immunogenicity and Reactogenicity: A Post Hoc Analysis of 2 Phase 3 Studies With the Adjuvanted Recombinant Zoster Vaccine
por: Callegaro, Andrea, et al.
Publicado: (2021)

26. Is There a Correlation Between Reactogenicity and Immune Responses of the Adjuvanted Recombinant Zoster Vaccine (RZV)? A Post-hoc Analysis
por: Callegaro, Andrea, et al.
Publicado: (2021)

Efficacy and serious adverse events profile of the adjuvanted recombinant zoster vaccine in adults with pre-existing potential immune-mediated diseases: a pooled post hoc analysis on two parallel randomized trials
por: Dagnew, Alemnew F, et al.
Publicado: (2020)

2778. Impact of Reactogenicity on Quality of Life and Physical Functioning in Adults ≥50 Years Receiving Both Doses of the Adjuvanted Recombinant Zoster Vaccine
por: Schmader, Kenneth E, et al.
Publicado: (2019)

Impact of Reactogenicity After Two Doses of Recombinant Zoster Vaccine Upon Physical Functioning and Quality of Life: An Open Phase III Trial in Older Adults
por: Schmader, Kenneth E, et al.
Publicado: (2020)

Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials
por: Oostvogels, Lidia, et al.
Publicado: (2019)

5. How Does Frailty Impact the Efficacy, Reactogenicity, Immunogenicity and Safety of the Adjuvanted Recombinant Zoster Vaccine? A Secondary Analysis of the ZOE-50 and ZOE-70 Studies
por: Andrew, Melissa K, et al.
Publicado: (2020)

The Impact of Reactogenicity After the First Dose of Recombinant Zoster Vaccine on the Physical Functioning and Quality of Life of Older Adults: An Open-Label, Phase III Trial
por: Schmader, Kenneth E, et al.
Publicado: (2019)

2488. The Impact of Reactogenicity After Administration of the Recombinant Zoster Vaccine Upon the Physical Functioning and Quality of Life of Older Adults
por: Schmader, Kenneth E, et al.
Publicado: (2018)

Assessment of the potential public health impact of Herpes Zoster vaccination in Germany
por: Curran, Desmond, et al.
Publicado: (2017)

Recombinant Zoster Vaccine Is Efficacious and Safe in Frail Individuals
por: Curran, Desmond, et al.
Publicado: (2020)

Safety and immunogenicity of an AS01-adjuvanted varicella zoster virus subunit candidate vaccine (HZ/su): A phase-I, open-label study in Japanese adults
por: Lal, Himal, et al.
Publicado: (2013)

2905. Long-term Immunological Persistence of the Adjuvanted Recombinant Zoster Vaccine: Clinical Data and Mathematical Modeling
por: Bastidas, Adriana, et al.
Publicado: (2019)

1956. Persistence of Immune Response and Safety of an Adjuvanted Recombinant Zoster Vaccine in Older Adults Previously Vaccinated with a Live-Attenuated Herpes Zoster Vaccine: End-of-Study Results of a Phase III, Group-Matched, Clinical Trial
por: Mrkvan, Tomas, et al.
Publicado: (2018)

Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Candidate Vaccine in Adults with Hematologic Malignancies: A Phase III, Randomized Clinical Trial
por: Oostvogels, Lidia
Publicado: (2017)

Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine: Persistence and Anamnestic Response to Additional Doses Administered 10 Years After Primary Vaccination
por: Hastie, Andrew, et al.
Publicado: (2020)

Safety and reactogenicity of second booster doses for mRNA vaccines
por: Wilder-Smith, Annelies, et al.
Publicado: (2023)

36. Safety and Reactogenicity of the Adjuvanted Recombinant Zoster Vaccine after Allogeneic Hematopoietic Stem Cell Transplantation
por: Baumrin, Emily, et al.
Publicado: (2020)

Safety and reactogenicity of the adjuvanted recombinant zoster vaccine: experience from clinical trials and post-marketing surveillance
por: Fiore, Joseph, et al.
Publicado: (2021)

149. Immunogenicity, Safety, and Post-hoc Efficacy Assessment of the Adjuvanted Recombinant Zoster Vaccine in Adults with Hematologic Malignancies: A Phase 3, Randomized Clinical Trial
por: Dagnew, Alemnew F, et al.
Publicado: (2018)

The Adjuvanted Recombinant Zoster Vaccine in Adults Aged ≥65 Years Previously Vaccinated With a Live-Attenuated Herpes Zoster Vaccine
por: Dagnew, Alemnew F, et al.
Publicado: (2020)

The adjuvanted recombinant zoster vaccine is efficacious and safe in Asian adults ≥ 50 years of age: a sub-cohort analysis of the ZOE-50 and ZOE-70 randomized trials
por: Kim, Joon Hyung, et al.
Publicado: (2021)

Quality of Life Impact of an Adjuvanted Recombinant Zoster Vaccine in Adults Aged 50 Years and Older
por: Curran, Desmond, et al.
Publicado: (2019)

Adjuvanted recombinant zoster vaccine decreases herpes zoster-associated pain and the use of pain medication across 3 randomized, placebo-controlled trials
por: Kim, Joon Hyung, et al.
Publicado: (2023)

Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine
por: Grupping, Katrijn, et al.
Publicado: (2017)

The how’s and what’s of vaccine reactogenicity
por: Hervé, Caroline, et al.
Publicado: (2019)

4. Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Adults
por: Dagnew, Alemnew F, et al.
Publicado: (2020)

Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults Previously Vaccinated with a Live-Attenuated Herpes Zoster Vaccine: A Phase III, Group-Matched, Clinical Trial
por: Grupping, Katrijn, et al.
Publicado: (2017)

Humoral immunogenicity and reactogenicity of CoronaVac or ZF2001 booster after two doses of inactivated vaccine
por: Cao, Yunlong, et al.
Publicado: (2021)

7. Can Recombinant Zoster Vaccine Administration Decrease the Use of Herpes Zoster-related Pain Medication Across Randomized Controlled Studies?
por: Kim, Joon Hyung, et al.
Publicado: (2020)

Incidence of Herpes Zoster and Persistent Post-Zoster Pain in Adults With or Without Diabetes in the United States
por: Suaya, Jose A., et al.
Publicado: (2014)

The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70
por: Boutry, Céline, et al.
Publicado: (2021)

Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated vaccine
por: Kanokudom, Sitthichai, et al.
Publicado: (2022)

Assurance in vaccine efficacy clinical trial design based on immunological responses
por: Callegaro, Andrea, et al.
Publicado: (2021)

Immune responses to the adjuvanted recombinant zoster vaccine in immunocompromised adults: a comprehensive overview
por: Dagnew, Alemnew F., et al.
Publicado: (2021)

8. The Adjuvanted Recombinant Zoster Vaccine (RZV) Confers Long-term Protection Against Herpes Zoster: Interim Results of an Extension Study (ZOSTER-049) of Two Clinical Trials (ZOE-50 and ZOE-70)
por: Boutry, Céline, et al.
Publicado: (2020)

Reactogenicity, safety and antibody response, after one and two doses of mRNA-1273 in seronegative and seropositive healthcare workers
por: Tré-Hardy, Marie, et al.
Publicado: (2021)

Effect of a single dose of pregabalin on herpes zoster pain
por: Jensen-Dahm, Christina, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_s18s5807nh3t9e0j076oc6tb5g